Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (852)	3/16/2000 8:54:00 PM
From: A.J. Mullen	Respond to of 52153

"Hopefully everyone will cross-license, otherwise it's only the lawyers that will get rich." At the H&Q Lifesciences meeting, Roy Whitfield, CEO of Incyte ,said that with everyone having a stake in everyone else's work, there was every incentive to do just that. It was general posture of all the presenters I heard. My nagging worry is that anyone with a consistently small stake in many ventures has the potential to be a spoiler, and hold-out for more than there IPR would otherwise be worth. They would have less incentive to settle. Jon Koplik has posted that Wall St. J. article on the HGSI thread. I thought it fair and made a number of good points. Ironic that HGSI is at the one that has attracted all the attention for claiming rights for simply describing a gene, when they see themselves as far above that sort of thing. Jon also posted another article suggesting that the release of the Bill & Tony opinion had unfortunate timing. Let's hope neither of them announce that the sun is likely to set. Imagine the strain that would put on the market!